A single pill in a blister pack on a counter beside a glass of water

· updated

Foundayo for Sleep Apnea: What the ATTAIN-OSA Trials Found


Short answer: a daily pill just worked on sleep apnea in two big trials. In results published in JAMA on Nov 9, 2026, Lilly’s Foundayo (orforglipron) cut breathing interruptions by about 12 to 13 more events per hour than placebo over 52 weeks, in people who use CPAP and in people who do not. It is not approved for sleep apnea yet. Lilly plans to ask the FDA by the end of 2026.

Key facts

What is ATTAIN-OSA?

ATTAIN-OSA is Lilly’s phase 3 program testing Foundayo in obstructive sleep apnea (OSA), the kind where your airway collapses during sleep and breathing keeps stopping or going shallow. It was two separate randomized, double-blind, placebo-controlled trials, which is the strongest kind of evidence a drug gets before approval.

Everyone got diet and lifestyle counseling. People with diabetes were left out, per Healio. The dose was stepped up over time to the highest level each person tolerated. Lilly funded both trials.

The main score was the apnea-hypopnea index (AHI): how many times per hour breathing stops or drops off during sleep. At the start, people averaged 50.7 events an hour in trial 1 and 57.6 in trial 2. That is a lot of broken sleep.

How well did it work?

Using the stricter JAMA analysis, which counts everyone randomized whether or not they stayed on the pill:

Result at 52 weeks Foundayo Placebo
AHI change, no CPAP (trial 1) -17.8 events/hour -4.5
AHI change, on CPAP (trial 2) -17.3 events/hour -5.3
Body weight, trial 1 -10.4% -2.2%
Body weight, trial 2 -10.7% -1.1%

Both AHI results were statistically significant (P < .001), and 6 of 7 key secondary goals also came out in Foundayo’s favor, per JAMA.

Lilly’s own headline numbers are bigger because they use an “efficacy estimand,” a method that assumes everyone stayed on the drug the whole year. On that basis, AHI fell 43.8% vs 6.3% without CPAP and 27.5% vs 3.0% with CPAP, and 31.5% of the no-CPAP group reached remission or mild sleep apnea, per Medical Daily. Both views are real; the JAMA numbers are closer to what happens when real people drop out.

Other gains, per Healio: systolic blood pressure fell 7 to 8 mm Hg vs 1 to 3 mm Hg on placebo, and hsCRP, a blood marker of inflammation, fell 38% to 42% vs 4% to 18%. For scale, presenter Dr. Vaishnavi Kundel said CPAP alone usually lowers systolic pressure by about 2 to 3 mm Hg.

Why this is good news

Sleep apnea treatment has mostly meant a mask every night. A lot of people hate it or quit. Zepbound, a weekly shot, was approved for moderate to severe OSA with obesity in 2024, per Healio. A pill would be a third option.

“There are no current oral treatments for sleep apnea,” sleep researcher Grandner told Healio, calling an oral option “a game changer.” Sarraju of Cleveland Clinic, writing a Perspective, described orforglipron as “the first-ever oral therapy that is showing benefits for moderate to severe obstructive sleep apnea.”

The researchers were clear it is not meant to replace CPAP. It could sit alongside the machine, or help people who cannot use one.

Update, Nov 20, 2026: Lilly’s weekly shot retatrutide, which is still investigational, now has phase 3 sleep apnea results too. See retatrutide for sleep apnea.

Side note for the peptide crowd: Foundayo is a small molecule, not a peptide, even though it acts on the same GLP-1 receptor as semaglutide and tirzepatide. Our explainer on whether GLP-1s are peptides covers the difference.

The fine print

Promising and not finished can both be true:

What it means for you

If you snore hard, wake up wrecked, or quit your CPAP, the first step has not changed: get a sleep study and a diagnosis. If you have OSA and obesity, a weekly shot (Zepbound) is already approved for it, and a daily pill could join it if the FDA approves Lilly’s planned filing. A licensed provider can tell you whether you qualify for either, how they fit with CPAP, and what the side effects look like for you. Our Oral Wegovy vs Foundayo guide compares the two GLP-1 pills, Zepbound and Foundayo on Hims & Hers covers how people get them today, our GLP-1 telehealth guide explains online prescribing, and the legal status tracker covers where unapproved peptides stand.

Sources

Educational content only, not medical advice. Foundayo is not FDA-approved for sleep apnea as of Nov 10, 2026; talk to a licensed provider about diagnosis and treatment options.

← All articles